MedCompanion

Acute Cholangitis / Cholecystitis

Abdominal/Pelvic

Source: IDMP View on spectrum chart →
Patient + scenario modifiers
Patient
Clinical scenario / source

Annotations only — chart still shows the full chemistry of each drug.

1. Clinical Syndrome

Biliary tract infection requiring source control (drainage/surgery) plus antibiotics.

Acute cholangitis — infection of biliary tree, classically obstructive (choledocholithiasis, malignancy, stricture, stent). Charcot triad: RUQ pain + jaundice + fever. Reynolds pentad adds altered mentation + shock. Tokyo 2018 grading: Grade I (mild — meets dx criteria), Grade II (moderate — WBC >12 or <4, fever >39, age ≥75, bili ≥5, alb <3.5), Grade III (severe — organ dysfunction).

Acute cholecystitis — infection of gallbladder wall, almost always calculous (≥90%); acalculous cholecystitis in critically ill, TPN-dependent, post-op. Murphy sign, RUQ pain, fever, leukocytosis. Tokyo 2018 grading parallels cholangitis.

Excludes: asymptomatic choledocholithiasis (no infection — ERCP for stone, no abx), uncomplicated biliary colic, primary biliary cholangitis / primary sclerosing cholangitis without acute superinfection.

2. Pathogens

Consider the patient: Prior biliary instrumentation (stent, ERCP, biliary-enteric anastomosis — dramatically broadens flora + adds anaerobes), healthcare exposure, immunocompromise (Candida risk), advanced age (more severe disease, more comorbid), recent abx exposure (MDRO).

Consider the case: Community-acquired vs healthcare-associated (latter has 2–3× rate of Pseudomonas, ESBL, VRE, Candida). Severity grade (Tokyo I/II/III) — drives empiric breadth + urgency of source control. Source amenable to drainage? ERCP (cholangitis), perc cholecystostomy or cholecystectomy (cholecystitis).

Common

    • Escherichia coli

      Most common pathogen across all biliary infection severity (~40–50%).

    • Klebsiella pneumoniae

      Second most common GNR; ESBL rates rise with healthcare exposure.

    • Enterococcus faecalis

      Common — esp post-instrumentation, biliary-enteric anastomosis, healthcare-associated. Routine coverage in severe / healthcare-associated; not routinely in mild community-acquired.

    • Bacteroides fragilis

      Anaerobic coverage essential when biliary-enteric anastomosis, gangrenous / emphysematous cholecystitis, or chronic biliary obstruction.

Less common

    • Pseudomonas aeruginosa

      Post-ERCP, indwelling stent, healthcare-associated, prior broad abx. Routine coverage in Tokyo Grade III or healthcare-associated.

    • Enterococcus faecium (VRE)

      Liver transplant, prolonged hospitalization, prior vancomycin.

    • Candida albicans

      Post-op, recurrent biliary instrumentation, prolonged broad abx, immunocompromised.

    • Clostridioides difficile

      Not biliary pathogen but watch for CDI complication of prolonged broad abx in this population.

3. Empiric Therapy

TierFirst choiceAlternativesDurationComments
Outpatient — with comorbidities
  • 500 mg · PO BID · PO · 4–7 days after source control
  • 500 mg · PO TID · PO

    Add only if biliary-enteric anastomosis or otherwise anaerobe-relevant.

  • 875 mg · PO BID · PO

    Covers strep, enterococcus (E. faecalis), anaerobes — useful single-agent for mild outpatient cases.

4–7 days after source control**Tokyo Grade I, source-controlled, no comorbidity / sepsis.** Rare to manage purely outpatient — most need admission for ERCP / cholecystectomy.
Admitted to ward
  • 2 g · q24h · IV · 4–7 days after source control
  • 500 mg · q8h · IV

    Add for biliary-enteric anastomosis, gangrenous / emphysematous cholecystitis, or chronic biliary obstruction.

  • 3 g · q6h · IV

    Covers strep, enterococcus, anaerobes — useful if enterococcus coverage desired. Rising B. fragilis resistance limits use in severe disease.

  • 1 g · q24h · IV

    OPAT-friendly; covers anaerobes; useful for moderate severity not requiring anti-pseudomonal coverage.

4–7 days after source control (Tokyo I/II); 10–14 days if bacteremia**Tokyo Grade I/II, community-acquired.** Source control first (ERCP for cholangitis, cholecystectomy / perc chole for cholecystitis). Don't routinely cover enterococcus in mild community-acquired disease.
Admitted to ICU
  • 4.5 g · q6h (extended infusion) · IV · 7–10 days after source control
  • 1 g · q8h · IV

    Prior ESBL, severe healthcare-associated, or carbapenem-sparing not feasible.

7–10 days after source control (10–14 days if bacteremia)**Tokyo Grade III or healthcare-associated severe biliary infection.** Pip-tazo covers GNR + anaerobes + enterococcus (faecalis). Source control urgent — emergent ERCP < 12–24 h for Grade III cholangitis.
ICU — Pseudomonas risk
  • 4.5 g · q6h · IV
  • load + AUC-guided · — · IV

    Add if MRSA risk or severe healthcare-associated.

  • 1 g · q8h · IV

    If ESBL risk.

  • 100 mg · q24h · IV

    Add empiric antifungal if recurrent biliary instrumentation, prolonged broad abx, post-op, or immunocompromised — esp septic shock without rapid improvement.

7–14 days after source control; antifungal continues 14 days from first negative if Candida grows**Septic shock + healthcare exposure / liver transplant / recurrent instrumentation.** Discuss with ID + surgery / IR for urgent source control.

Add coverage if:

MRSA coverage
  • Known MRSA colonization
  • Healthcare-associated severe disease
  • Persistent positive cultures

Add:

  • load + AUC-guided · — · IV
Pseudomonas coverage
  • Post-ERCP / indwelling biliary stent
  • Healthcare-associated
  • Recent broad-spectrum abx
  • Tokyo Grade III

Add:

  • 4.5 g · q6h · IV

    Or cefepime / meropenem.

ESBL coverage
  • Prior ESBL isolate
  • Broad-spectrum abx within 90 days
  • Healthcare-associated severe disease

Add:

  • 1 g · q8h · IV

    Or ertapenem if not septic.

VRE coverage
  • Prior VRE colonization
  • Liver transplant
  • Prolonged broad-spectrum coverage

Add:

  • 600 mg · q12h · IV/PO
  • 8–10 mg/kg · q24h · IV

    Alternative.

Candida coverage
  • Post-op biliary surgery
  • Recurrent biliary instrumentation
  • Prolonged broad-spectrum abx
  • Immunocompromise / liver transplant
  • Multifocal Candida colonization

Add:

  • 100 mg · q24h · IV

    Step down to fluconazole if C. albicans susceptible.

4. Directed Therapy

Source control is the priority — antibiotics without drainage fail in obstructed biliary infection.

Acute cholangitis:

  • Grade III (severe): emergent ERCP within 12–24 h. If ERCP unsuccessful → percutaneous transhepatic biliary drainage (PTC).
  • Grade II (moderate): ERCP within 24–48 h or earlier if not improving.
  • Grade I (mild): ERCP within 1–2 days; some can be managed with abx alone if obstruction resolves (small stone passes spontaneously).

Acute cholecystitis:

  • Standard: early laparoscopic cholecystectomy within 72 h (TG18 + multiple RCTs — equivalent or better outcomes than delayed).
  • High surgical risk / acalculous in critically ill: percutaneous cholecystostomy.
  • Grade I uncomplicated: can sometimes manage with abx + delayed elective cholecystectomy in 6 weeks.

Duration after source control:

  • Adequately drained Grade I/II biliary infection: 4 days after source control is enough (STOP-IT trial — same as cIAI).
  • Severe / Grade III / bacteremia: 7–14 days.
  • Persistent bacteremia or failed source control → reimage, extend.

Narrow to culture data — bile cultures + blood cultures should be obtained during drainage. ESBL E. coli / Klebsiella → carbapenem. Pseudomonas → susceptible anti-pseudomonal β-lactam. VRE → linezolid / daptomycin. Candida → echinocandin → fluconazole step-down if susceptible.

5. Monitoring

Resolution: fever curve, WBC, LFTs (cholangitis — direct bili / alk phos should trend down post-drainage), abdominal exam, lactate. Repeat imaging at 48–72 h if not improving.

Persistent fever / leukocytosis at 48–72 h → reimage (retained stone? abscess? failed drainage?). Repeat ERCP / IR drainage may be needed.

Bacteremia rate: 30–50% in cholangitis — pursue 10–14 day course if positive blood cultures.

Toxicity: vanc AUC + Cr; pip-tazo + vanc AKI risk; metronidazole prolonged → neuropathy; CDI risk with prolonged broad abx in elderly hospitalized patients.

Pearls

Source control beats antibiotics. ERCP for cholangitis. Cholecystectomy (or perc chole if too sick) for cholecystitis. Tokyo Guidelines 2018 (TG18) structure the severity grading and time-to-drainage decision. Charcot triad (~50–70% sensitivity for cholangitis) → Reynolds pentad (shock + AMS) is severe. Don't routinely cover enterococcus in mild community-acquired biliary infection — yields skinny benefit, broad selection. Always cover enterococcus in severe / healthcare-associated / biliary-enteric anastomosis / transplant. Anaerobe coverage mandatory when biliary-enteric anastomosis, gangrenous / emphysematous cholecystitis. Post-ERCP cholangitis with stent in situ = healthcare-associated — broaden empirics, expect MDRO. 4 days after source control is enough for mild/moderate adequately drained disease (STOP-IT logic applies).

References